Mary Lou Chatterton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9528399/publications.pdf

Version: 2024-02-01

47 papers

2,566 citations

394421 19 h-index 254184 43 g-index

50 all docs

50 docs citations

times ranked

50

3594 citing authors

#	Article	IF	CITATIONS
1	Patterns of psychiatric admission in Australian pregnant and childbearing women. Social Psychiatry and Psychiatric Epidemiology, 2022, 57, 611-621.	3.1	1
2	Healthcare costs and resource use associated with negative symptoms of schizophrenia: A systematic literature review. Schizophrenia Research, 2022, 241, 251-259.	2.0	14
3	Cost-utility analysis of rTMS as add-on therapy to standard care for the treatment of hallucinations in schizophrenia. European Psychiatry, 2022, , 1-32.	0.2	O
4	Evaluating telehealth lifestyle therapy versus telehealth psychotherapy for reducing depression in adults with COVID-19 related distress: the curbing anxiety and depression using lifestyle medicine (CALM) randomised non-inferiority trial protocol. BMC Psychiatry, 2022, 22, 219.	2.6	3
5	Low intensity treatment for clinically anxious youth: a randomised controlled comparison against face-to-face intervention. European Child and Adolescent Psychiatry, 2021, 30, 1071-1079.	4.7	6
6	Clinical efficacy of a Decision Support Tool (Link-me) to guide intensity of mental health care in primary practice: a pragmatic stratified randomised controlled trial. Lancet Psychiatry,the, 2021, 8, 202-214.	7.4	22
7	Scoping review: Development and assessment of evaluation frameworks of mobile health apps for recommendations to consumers. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1318-1329.	4.4	43
8	The Productivity Commission Inquiry Report into Mental Health $\hat{a} \in \text{``}$ A Commentary from a Health Economics Perspective. Australian Economic Review, 2021, 54, 119-129.	0.7	3
9	The cost of Medicare-funded medical and pharmaceutical services for mental disorders in children and adolescents in Australia. PLoS ONE, 2021, 16, e0249902.	2.5	10
10	Burden and preference-based quality of life associated with bullying in children. European Child and Adolescent Psychiatry, $2021, 1.$	4.7	3
11	Cost-effectiveness evidence of mental health prevention and promotion interventions: A systematic review of economic evaluations. PLoS Medicine, 2021, 18, e1003606.	8.4	64
12	Australian adolescent population norms for the child health utility index 9Dâ€"results from the young minds matter survey. Quality of Life Research, 2021, 30, 2895-2906.	3.1	7
13	To the Editor: Authors' response to "New approaches towards actionable mobile health evaluation― by John Torous and Sarah Lagan. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 2308-2309.	4.4	0
14	Matching depression management to severity prognosis in primary care: results of the Target-D randomised controlled trial. British Journal of General Practice, 2021, 71, e85-e94.	1.4	16
15	The Moo'D Study: protocol for a randomised controlled trial of A2 beta-casein only versus conventional dairy products in women with low mood. Trials, 2021, 22, 899.	1.6	1
16	The economic costs of loneliness: a review of cost-of-illness and economic evaluation studies. Social Psychiatry and Psychiatric Epidemiology, 2020, 55, 823-836.	3.1	55
17	Whither economic evaluation in the case of COVID-19: What can the field of mental health economics contribute within the Australian context?. Australian and New Zealand Journal of Psychiatry, 2020, 54, 1157-1161.	2.3	1
18	Cost-effectiveness of preventing child internalising problems: Results from the translational trial of Cool Little Kids at school entry. Journal of Anxiety Disorders, 2020, 70, 102191.	3.2	12

#	Article	IF	CITATIONS
19	The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry,the, 2019, 6, 675-712.	7.4	815
20	The cost-effectiveness of stepped care for the treatment of anxiety disorders in adults: A model-based economic analysis for the Australian setting. Journal of Psychosomatic Research, 2019, 125, 109812.	2.6	8
21	Policy Impacts of the Australian National Perinatal Depression Initiative: Psychiatric Admission in the First Postnatal Year. Administration and Policy in Mental Health and Mental Health Services Research, 2019, 46, 277-287.	2.1	11
22	Economic evaluation of stepped care for the management of childhood anxiety disorders: Results from a randomised trial. Australian and New Zealand Journal of Psychiatry, 2019, 53, 673-682.	2.3	28
23	Link-me: Protocol for a randomised controlled trial of a systematic approach to stepped mental health care in primary care. Contemporary Clinical Trials, 2019, 78, 63-75.	1.8	4
24	Efficacy of adjunctive Garcinia mangostana Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trial. Revista Brasileira De Psiquiatria, 2019, 41, 245-253.	1.7	8
25	The Cost-Effectiveness of an Internet Intervention to Facilitate Mental Health Help-Seeking by Young Adults: Randomized Controlled Trial. Journal of Medical Internet Research, 2019, 21, e13065.	4.3	22
26	Health state utility values of high prevalence mental disorders in Australia: results from the National Survey of Mental Health and Wellbeing. Quality of Life Research, 2018, 27, 1815-1825.	3.1	6
27	The SMILES trial: an important first step. BMC Medicine, 2018, 16, 237.	5.5	4
28	Mental health consultations in the perinatal period: a cost-analysis of Medicare services provided to women during a period of intense mental health reform in Australia. Australian Health Review, 2018, 42, 514.	1.1	8
29	Economic evaluation of a dietary intervention for adults with major depression (the "SMILES―trial). BMC Public Health, 2018, 18, 599.	2.9	50
30	Evaluating the Long-Term Effectiveness of School-Based Depression, Anxiety, and Substance Use Prevention Into Young Adulthood: Protocol for the Climate School Combined Study. JMIR Research Protocols, 2018, 7, e11372.	1.0	6
31	Psychosocial therapies for the adjunctive treatment of bipolar disorder in adults: Network meta-analysis. British Journal of Psychiatry, 2017, 210, 333-341.	2.8	109
32	A randomised controlled trial of dietary improvement for adults with major depression (the  SMILES') Tj E	TQq0 ₀ 0001	rgBTJOverloch
33	Cost-Effectiveness of Interventions for Anxiety and Depressive Disorders. , 2017, , 283-298.		1
34	Cost of high prevalence mental disorders: Findings from the 2007 Australian National Survey of Mental Health and Wellbeing. Australian and New Zealand Journal of Psychiatry, 2017, 51, 1198-1211.	2.3	63
35	Comparison of Stepped Care Delivery AgainstÂaÂSingle, Empirically Validated Cognitive-Behavioral Therapy Program for Youth With Anxiety: A Randomized Clinical Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, 841-848.	0.5	53
36	Economic evaluation of a psychological intervention for high distress cancer patients and carers: costs and qualityâ€adjusted life years. Psycho-Oncology, 2016, 25, 857-864.	2.3	17

#	Article	IF	Citations
37	The population costâ€effectiveness of a parenting intervention designed to prevent anxiety disorders inÂchildren. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2015, 56, 1026-1033.	5.2	34
38	Economic evaluations of interventions designed to prevent mental disorders: a systematic review. Microbial Biotechnology, 2015, 9, 85-92.	1.7	54
39	A randomised, controlled trial of a dietary intervention for adults with major depression (the) Tj ETQq1 1 0.7843	14 rgBT /C	Overlock 10T
40	Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. International Journal of Neuropsychopharmacology, 2011, 14, 1029-1049.	2.1	86
41	Treatment Options for Bipolar Depression. Journal of Clinical Psychopharmacology, 2010, 30, 579-590.	1.4	101
42	Economic Outcomes Associated With Atypical Antipsychotics in Bipolar Disorder. Primary Care Companion To the Journal of Clinical Psychiatry, 2007, 09, 419-428.	0.6	8
43	The family impact and costs of migraine. American Journal of Managed Care, 2004, 10, 313-20.	1.1	28
44	Reliability and Validity of the Migraine Therapy Assessment Questionnaire. Headache, 2002, 42, 1006-1015.	3.9	33
45	Cost-Effectiveness and Cost-Benefit of Sumatriptan in Patients With Migraine. Mayo Clinic Proceedings, 2001, 76, 1093-1101.	3.0	44
46	Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clinical Therapeutics, 2000, 22, 1357-1369.	2.5	57
47	Quality Improvement and Outcomes Measurement for the Oral and Maxillofacial Surgeon. Oral and Maxillofacial Surgery Clinics of North America, 1999, 11, 441-452.	1.0	0